Alfred von Krempelhuber

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial

Edgar T. Overton, Jack T. Stapleton, Ian Frank et al. · Open Forum Infectious Diseases · 2015 · 140 citations · Full text

Vaccination, Vaccine Safety, Vaccinology +15

Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects

Richard N. Greenberg, Edgar T. Overton, David W. Haas et al. · The Journal of Infectious Diseases · 2012 · 131 citations · Full text

A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE®

Alfred von Krempelhuber, Jens Vollmar, Rolf Pokorny et al. · Vaccine · 2009 · 122 citations · Full text

Vaccinology, Vaccine Safety, Vaccination +8

A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis

Richard N. Greenberg, Yadira Hurley, Dinh V. Dinh et al. · PLoS ONE · 2015 · 113 citations · Full text

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects

Richard N. Greenberg, Christine M. Hay, Jack T. Stapleton et al. · PLoS ONE · 2016 · 80 citations · Full text